Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3081-3091

  Lin, Biaoyang ^a,d   White, James T ^a   Lu, Wei ^a   Xie, Tao ^a   Utleg, Angelita G ^a   Yan, Xiaowei ^a   Yi, Eugene C ^a   Shannon, Paul ^a   Khrebtukova, Irina ^c   Lange, Paul H ^b   Goodlett, David R ^a   Zhou, Daixing ^c   Vasicek, Thomas J ^c   Hood, Leroy ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ILLUMINA INC   (United States)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ISOTOPE; MESSENGER RNA; PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR;

ARTICLE; BIOTECHNOLOGY; CANCER CELL CULTURE; CANCER GENETICS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DOWN REGULATION; GENE; GENE EXPRESSION; GENE MAPPING; GENETIC CODE; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STRUCTURAL PROTEOMICS; TANDEM MASS SPECTROMETRY; UNINDEXED SEQUENCE; UPREGULATION;

EID: 20244387835     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3218     Document Type: Article

References (43)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-73.
3. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
4. Vaarala MH, Porvari K, Kyllonen A, Vihko P. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 2000;80:1259-68.
5. Chang GT, Blok LJ, Steenbeek M, et al. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 1997;57:4075-81.
6. Brenner S, Johnson M, Bridgham J, et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol 2000;18:630-4.
7. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-13.
8. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-9.
9. Patel BJ, Pantuck AJ, Zisman A, et al. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-5.
10. Tso CL, McBride WH, Sun J, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J Sci Am 2000;6:220-33.
11. Meyers BC, Tej SS, Vu TH, et al. The use of MPSS for whole-genome transcriptional analysis in Arabidopsis. Genome Res 2004;14:1641-53.
12. Jongeneel CV, Iseli C, Stevenson BJ, et al. Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A 2003;100:4702-5.
13. Man MZ, Wang X, Wang Y. POWER_SAGE: comparing statistical tests for SAGE experiments. Bioinformatics 2000;16:953-9.
14. Kal AJ, van Zonneveld AJ, Benes V, et al. Dynamics of gene expression revealed by comparison of serial analysis of gene expression transcript profiles from yeast grown on two different carbon sources. Mol Biol Cell 1999;10:1859-72.
15. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 2001;19:946-51.
16. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-92.
17. Li XJ, Zhang H, Ranish JA, Aebersold R. Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal Chem 2003;75:6648-57.
18. Chen Y, Yu P, Luo J, Jiang Y. Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT. Mamm Genome 2003;14:859-65.
19. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55:71-80.
20. Hill AA, Hunter CP, Tsung BT, Tucker-Kellogg G, Brown EL. Genomic analysis of gene expression in C. elegans. Science 2000;290:809-12.
21. Han M, Gao X, Su JZ, Nie S. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol 2001;19:631-5.
22. Bao P, Frutos AG, Greef C, et al. High-sensitivity detection of DNA hybridization on microarrays using resonance light scattering. Anal Chem 2002;74:1792-7.
23. Velculescu VE, Vogelstein B, Kinzler KW. Analysing uncharted transcriptomes with SAGE. Trends Genet 2000;16:423-5.
24. Lal A, Lash AE, Altschul SF, et al. A public database for gene expression in human cancers. Cancer Res 1999;59:5403-7.
25. Liu AY, True LD, LaTray L, et al. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 1999;40:192-9.
26. Perrin BJ, Huttenlocher A. Calpain. Int J Biochem Cell Biol 2002;34:722-5.
27. Pandian SS, Eremin OE, McClinton S, Wahle KW, Heys SD. Fatty acids and prostate cancer: current status and future challenges. J R Coll Surg Edinb 1999;44:352-61.
28. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004;171:S19-24.
29. Cardo-Vila M, Arden KC, Cavenee WK, Pasqualini R, Arap W. Is Annexin 7 a tumor suppressor gene in prostate cancer? Pharmacogenomics J 2001;1:92-4.
30. Liu JW, Shen JJ, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003;22:1475-85.
31. Chi SG, deVere White RW, Muenzer JT, Gumerlock PH. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997;3:1889-97.
32. Cole KA, Chuaqui RF, Katz K, et al. cDNA sequencing and analysis of POV1 (PB39): a novel gene up-regulated in prostate cancer. Genomics 1998;51:282-7.
33. Kallakury BV, Sheehan CE, Winn-Deen E, et al. Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 2001;92:2786-95.
34. Vaarala MH, Porvari K, Kyllonen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 2001;94:705-10.
35. Prescott JL, Blok L, Tindall DJ. Isolation and androgen regulation of the human homeobox cDNA, NKX3.I. Prostate 1998;35:71-80.
36. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966-77.
37. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
38. Baliga NS, Bonneau R, Facciotti MT, et al. Genome sequence of Haloarcula marismortui: a halophilic archaeom from the Dead Sea. Genome Res 2004;14:2221-34.
39. Waghray A, Feroze F, Schober MS, et al. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 2001;1:1327-38.
40. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-13.
41. Rajagopalan LE, Malter JS. Regulation of eukaryotic messenger RNA turnover. Prog Nucleic Acid Res Mol Biol 1997;56:257-86.
42. Hood L, Perlmutter RM. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 2004;22:1215-7.
43. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004;306:640-3.